| Literature DB >> 20427086 |
Anjali S Advani1, Ramon Tiu, Yogen Saunthararajah, Jaroslaw Maciejewski, Edward A Copelan, Ronald Sobecks, Mikkael A Sekeres, Jennifer Bates, Mary Lynn Rush, Barbara Tripp, August Salvado, Elysa Noon, Matthew Howard, Tao Jin, Eric Hsi, Merrill J Egorin, Kathleen Lim, Claudiu V Cotta, Courtney Price, Matt Kalaycio.
Abstract
The c-kit receptor is expressed in 95% of relapsed acute myeloid leukemias (AMLs) and mediates leukemic proliferation. We conducted a Phase 1 study of the c-kit inhibitor, imatinib mesylate (IM), in combination with cytarabine and daunorubicin (7+3) in c-kit+ relapsed AML. IM was dose escalated using a 3 by 3 design. Phosphorylated STAT5 was absent to minimally present in residual blasts on day 14 bone marrows. The maximum tolerated dose of IM was 300 mg. The dose-limiting toxicity was Grade 3-4 hepatic toxicity. The CR/CRp rate was 57%. Cytotoxic therapy that includes IM for relapsed AML is well-tolerated and effective.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20427086 DOI： 10.1016/j.leukres.2010.03.021
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156